Literature DB >> 8891123

Disposition of intravenous metronidazole in Asian surgical patients.

T Y Ti1, H S Lee, Y M Khoo.   

Abstract

Steady-state peak and trough concentrations of metronidazole and its metabolites were measured in the sera of 54 surgical patients who were on intravenous metronidazole, 500 mg every 8 h. These patients had no significant renal or hepatic impairment. High-pressure liquid chromatography was used to determine the concentrations of metronidazole and its metabolites. The mean peak and trough metronidazole concentrations were 28.9 +/- 11.0 and 18.0 +/- 9.9 micrograms/ml, respectively. The acid metabolite was not detectable in all the blood specimens. The mean peak concentration of the hydroxy metabolite (MH) was 6.6 +/- 4.3 micrograms/ml, the mean trough concentration of MH was 6.2 +/- 4.2 micrograms/ml, and the MH concentration/metronidazole concentration ratio was 0.4 +/- 0.24. Using a population-based method for the pharmacokinetic analysis and stepwise regression between parameters and covariables (sex, age, and weight), we found that weight showed the highest correlation with the total body clearance (CL). The mean CL was 0.89 +/- 0.3 ml min-1 kg-1 (3.029 liters/h), the mean volume of distribution was 0.73 +/- 0.14 liter/kg, and the mean elimination half-life was 10.6 +/- 4.5 h. For the patients in our study, the CL was lower and the elimination half-life was longer compared with those for healthy volunteers, but the values of these parameters were comparable to those found for hospitalized patients. There was an inverse correlation between age and CL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891123      PMCID: PMC163512     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Twelve-hourly dosage schedule for oral and intravenous metronidazole.

Authors:  P Earl; P R Sisson; H R Ingham
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

2.  Pharmacokinetics of metronidazole in hospitalized patients.

Authors:  A Lau
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1986-12

3.  Single- and multiple-dose metronidazole kinetics.

Authors:  J C Jensen; R Gugler
Journal:  Clin Pharmacol Ther       Date:  1983-10       Impact factor: 6.875

4.  Age-associated pharmacokinetic changes of metronidazole.

Authors:  E Ludwig; A Csiba; T Magyar; G Szöcs; H Graber
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1983-02

5.  A rapid and specific semi-micro method involving high-pressure liquid chromatography for the assay of metronidazole in plasma, saliva, serum, urine and whole blood.

Authors:  C M Kaye; M G Sankey; L A Thomas
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

6.  Metronidazole clearance: a one-sample method and influencing factors.

Authors:  S Loft; H E Poulsen; J Sonne; M Døssing
Journal:  Clin Pharmacol Ther       Date:  1988-04       Impact factor: 6.875

7.  Pharmacokinetics of metronidazole and its metabolites in reduced renal function.

Authors:  T Bergan; S B Thorsteinsson
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

Review 8.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 9.  Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-11       Impact factor: 9.546

10.  Metronidazole elimination is preserved in the elderly.

Authors:  S Loft; C Egsmose; J Sonne; H E Poulsen; M Døssing; P B Andreasen
Journal:  Hum Exp Toxicol       Date:  1990-05       Impact factor: 2.903

View more
  4 in total

1.  In Vitro Study of the Susceptibility of Clinical Isolates of Trichomonas vaginalis to Metronidazole and Secnidazole.

Authors:  Arindam P Ghosh; Cheri Aycock; Jane R Schwebke
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 2.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 3.  Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.

Authors:  Sarah L Cudmore; Kiera L Delgaty; Shannon F Hayward-McClelland; Dino P Petrin; Gary E Garber
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 4.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.